5-Chloro-2-(4-chlorophenylsulfonylamino)-N-(2-naphthyl)benzamide | 254432-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-Chloro-2-(4-chlorophenylsulfonylamino)-N-(2-naphthyl)benzamide
• 英文别名: 5-chloro-2-[(4-chlorophenyl)sulfonylamino]-N-naphthalen-2-ylbenzamide
• CAS: 254432-26-3
• 化学式: C₂₃H₁₆Cl₂N₂O₃S
• 分子量: 471.364
• InChiKey: FAXSDFWGDRBDHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators
  申请人：Schindler Ursula

  公开号：US20050080073A1

  公开（公告）日：2005-04-14

  The present invention relates to compounds of the formula I in which A 1 , A 2 , R 2 and R 3 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention relates to the use of compounds of the formula I for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, novel compounds of the formula I, pharmaceutical preparations comprising them and processes for their preparation.

  本发明涉及式 I 的化合物 其中 A 1 , A 2 , R 2 和 R 3 具有权利要求中所述的含义，是治疗和预防疾病（例如高血压、心绞痛、心功能不全、血栓或动脉粥样硬化等心血管疾病）的重要药物活性化合物。式 I 的化合物具有调节环磷酸鸟苷（cGMP）内源性生成的能力，通常适用于治疗和预防与 cGMP 平衡紊乱有关的疾病状态。本发明涉及式 I 化合物在治疗和预防指定疾病状态中的用途及其药物生产、新型式 I 化合物、包含这些化合物的药物制剂及其制备工艺。
• SULFONYLAMINO-CARBONSÄURE-N-ARYLAMIDE ALS GUANYLATCYCLASE-AKTIVATOREN
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1095015B1

  公开（公告）日：2005-06-01
• Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20030171352A1

  公开（公告）日：2003-09-11

  The present invention relates to compounds of the formula I 1 in which A 1 , A 2 , R 2 and R 3 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention relates to the use of compounds of the formula I for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, novel compounds of the formula I, pharmaceutical preparations comprising them and processes for their preparation.
• US6548547B1
  申请人：——

  公开号：US6548547B1

  公开（公告）日：2003-04-15
• US6809089B2
  申请人：——

  公开号：US6809089B2

  公开（公告）日：2004-10-26